Literature DB >> 2453895

Buprenorphine and naloxone alone and in combination in opioid-dependent humans.

K L Preston1, G E Bigelow, I A Liebson.   

Abstract

Subjective, physiological and behavioral effects of subcutaneously administered hydromorphone (6 mg), naloxone (0.2 mg), buprenorphine (0.2 and 0.3 mg), and two buprenorphine-naloxone combinations (buprenorphine 0.2 mg plus naloxone 0.2 mg and buprenorphine 0.3 mg plus naloxone 0.2 mg) were assessed under double-blind conditions in six opioid-dependent volunteers. Physiologic measures and subject- and observer-rated behavioral responses were measured before dosing and for 120 min after drug administration. Hydromorphone decreased pupil diameter and respiration, increased blood pressure and increased scores on subjective measures indicating opioid-like effects. Buprenorphine given alone had no significant effect on any variable measured. Naloxone given alone produced opioid abstinence-like effects which were measurable on subject- and observer-rated behavioral measures and physiological measures. Buprenorphine in combination with naloxone somewhat attenuated the naloxone-precipitated withdrawal response. Overall, the naloxone-buprenorphine combinations produced effects which were qualitatively similar to the effects of naloxone alone, suggesting a low potential for abuse of the combination product by opioid-dependent individuals.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2453895     DOI: 10.1007/bf00212842

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Studies on N-allylnormorphine in man: antagonism to morphine and heroin and effects of mixtures of N-allylnormorphine and morphine.

Authors:  H F FRASER; C D VAN HORN; H ISBELL
Journal:  Am J Med Sci       Date:  1956-01       Impact factor: 2.378

2.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

3.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

Authors:  D R Jasinski; J S Pevnick; J D Griffith
Journal:  Arch Gen Psychiatry       Date:  1978-04

4.  Effects of short- and long-term administration of pentazocine in man.

Authors:  D R Jasinski; W R Martin; R D Hoeldtke
Journal:  Clin Pharmacol Ther       Date:  1970 May-Jun       Impact factor: 6.875

5.  Decline in abuse of pentazocine/tripelennamine (T's and Blues) associated with the addition of naloxone to pentazocine tablets.

Authors:  A Poklis
Journal:  Drug Alcohol Depend       Date:  1984-10       Impact factor: 4.492

6.  Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo.

Authors:  R R Griffiths; G E Bigelow; I Liebson; J E Kaliszak
Journal:  J Pharmacol Exp Ther       Date:  1980-12       Impact factor: 4.030

7.  Pharmacological study of pentazocine-naloxone combination: interest as a potentially non abusable oral form of pentazocine.

Authors:  J Legros; H Khalili-Varasteh; G Margetts
Journal:  Arch Int Pharmacodyn Ther       Date:  1984-09

8.  Methadone-naloxone mixtures for use in methadone maintenance programs. I. An evaluation in man of their pharmacological feasibility. II. Demonstration of acute physical dependence.

Authors:  J G Nutt; D R Jasinski
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

9.  Comparison of intramuscular buprenorphine and a buprenorphine/naloxone combination in the treatment of post-operative pain.

Authors:  B Vanacker; E Vandermeersch; J Tomassen
Journal:  Curr Med Res Opin       Date:  1986       Impact factor: 2.580

10.  A combination of buprenorphine and naloxone compared with buprenorphine administered intramuscularly in postoperative patients.

Authors:  G Rolly; J Poelaert; H Mungroop; H Paelinck
Journal:  J Int Med Res       Date:  1986       Impact factor: 1.671

View more
  19 in total

Review 1.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.

Authors:  Tammi Schaeffer
Journal:  J Med Toxicol       Date:  2012-12

Review 3.  Update on the clinical use of buprenorphine: in opioid-related disorders.

Authors:  Simon Ducharme; Ronald Fraser; Kathryn Gill
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

4.  Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.

Authors:  Angela N Duke; Christopher J Correia; Sharon L Walsh; George E Bigelow; Eric C Strain
Journal:  Psychopharmacology (Berl)       Date:  2010-06-25       Impact factor: 4.530

5.  Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.

Authors:  Sharon L Walsh; Paul A Nuzzo; Shanna Babalonis; Victoria Casselton; Michelle R Lofwall
Journal:  Drug Alcohol Depend       Date:  2016-03-14       Impact factor: 4.492

6.  Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers.

Authors:  Sandra D Comer; Eric D Collins
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

Review 7.  Narrative review: buprenorphine for opioid-dependent patients in office practice.

Authors:  Lynn E Sullivan; David A Fiellin
Journal:  Ann Intern Med       Date:  2008-05-06       Impact factor: 25.391

8.  Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study.

Authors:  Stacey C Sigmon; Kelly E Dunn; Gary J Badger; Sarah H Heil; Stephen T Higgins
Journal:  Addict Behav       Date:  2008-11-24       Impact factor: 3.913

9.  Buprenorphine for opioid dependence.

Authors:  Walter Ling
Journal:  Expert Rev Neurother       Date:  2009-05       Impact factor: 4.618

Review 10.  Practical considerations for the clinical use of buprenorphine.

Authors:  Hendree E Jones
Journal:  Sci Pract Perspect       Date:  2004-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.